Journal article
Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort
R Ataide, EA Ashley, R Powell, JA Chan, MJ Malloy, K O'Flaherty, E Takashima, C Langer, T Tsuboi, AM Dondorp, NP Day, M Dhorda, RM Fairhurst, P Lim, C Amaratunga, S Pukrittayakamee, TT Hien, Y Htut, M Mayxay, MA Faiz Show all
Proceedings of the National Academy of Sciences of the United States of America | NATL ACAD SCIENCES | Published : 2017
Abstract
Artemisinin-resistant falciparum malaria, defined by a slow-clearance phenotype and the presence of kelch13 mutants, has emerged in the Greater Mekong Subregion. Naturally acquired immunity to malaria clears parasites independent of antimalarial drugs. We hypothesized that between- and within-population variations in host immunity influence parasite clearance after artemisinin treatment and the interpretation of emerging artemisinin resistance. Antibodies specific to 12 Plasmodium falciparum sporozoite and blood-stage antigens were determined in 959 patients (from 11 sites in Southeast Asia) participating in a multinational cohort study assessing parasite clearance half-life (PCt1/2) after a..
View full abstractRelated Projects (2)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
We thank all the patients for their participation in these studies; TRAC study investigators; Bongkot Soonthornsata and Daniel Blessborn for their assistance in specimen management; Annie Mo (NIH) for providing EBA175RII; Robin Anders (La Trobe University) for providing MSP2; Alistair McLean, Jack Richards, and Andrew Guy for technical support; and Paul Newton and colleagues in Laos and TRAC investigators and colleagues in Cambodia for their efforts in support of this work. Antibody work and analysis was supported by the National Health and Medical Research Council of Australia [Project Grant 1060785 (to F.J.I.F., J.A.S., and F.N.), Program Grant APP637406 (to J.G.B.), training fellowship 637396 (to F.J.I.F.), and senior research fellowships APP1077636 (to J.G.B.) and 1104975 (J.A.S.)], the Australian Research Council [Future Fellowships FT130101122 (to F.J.I.F.) and FT0992317 (to J.G.B.)], Ramaciotti Establishment Grant 3245/2011 and Ian Potter Foundation Grant (to F.J.I.F.), and a Victorian State Government Operational Infrastructure Support grant. The clinical trials were funded by the UK Department for International Development, with additional support from the Worldwide Antimalarial Resistance Network and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. The trials were part of the Wellcome Trust Mahidol Oxford Tropical Medicine Research Programme funded by the Wellcome Trust of Great Britain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.